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FibroblastsWehave examined the effect of expression of the protein tyrosine phosphatase Shp2 on transformation by the
mouse polyoma virus middle T antigen (PyMT). Gain-of-function mutations in Shp2 indicate that it may serve
as an oncogene in several types of human leukemia. Paradoxically, however, some catalytically dominant-
negative mutations of Shp2 have also been identiﬁed in leukemia and neuroblastomas. In this study, we show
that Shp2 suppresses transformation induced by PyMT, the major polyoma viral oncoprotein known to act
through binding and activation of pp60c-src. Over-expression of a catalytically inactive Shp2 mutant in NIH3T3
cells signiﬁcantly enhanced PyMT-induced transformation. Conversely, re-introduction of Shp2 into Shp2-
deﬁcient cells strongly inhibited PyMT-induced transformation and tumorigenesis. Short hairpin RNA
(shRNA)-mediated Shp2 knockdown potentiated PyMT-induced transformation. Finally, we present evidence
that the transformation-suppressive effects of Shp2 are mediated at least partially through the inhibition of
signal transducers and activators of transcription 3.iology, Institute of Molecular
u, Beijing 100871, China. Fax:
jincailuo@pku.edu.cn (J. Luo).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Shp2, a ubiquitously expressed cytoplasmic protein tyrosine
phosphatase (PTP), is essential for the activation of mitogen activated
protein kinase (MAPK) by growth factors and cytokines, and favors
the promotion of cell proliferation (Neel et al., 2003; Feng, 2007;
Dance et al., 2008). Interestingly, Shp2 also negatively regulates
several signaling pathways, including the Stat signaling pathway, and
inhibits gliogenesis and lymphoid cell activation (Gauthier et al.,
2007; Sedy et al., 2005; Feng, 1999). So far, very little is known with
regard to any negative role that Shp2 plays in cancer signaling.
Genetic studies have identiﬁed somatic gain-of-function muta-
tions in PTPN11, which encodes the Shp2 tyrosine phosphatase, in
various types of leukemia with constitutively active phosphatase
activity, suggesting that Shp2 is a bona ﬁde oncogene (Chan and Feng,
2007; Mohi and Neel, 2007). Interestingly, loss-of-function germline
mutations in PTPN11 were also identiﬁed in LEOPARD (lentigines,
electrocardiogram abnormalities, ocular hypertelorism, pulmonic
valvular stenosis, abnormalities of genitalia, retardation of growth,
and deafness) syndrome with decreased phosphatase activity, in
association with acute myelogenous leukemia and neuroblastoma
(Mohi and Neel, 2007). Mutant Shp2 proteins, which are catalyticallydefective and dominant-negative, inhibit growth factor-evoked Erk
activation (Kontaridis et al., 2006). Shp2 has also been shown to
inhibit transformation of a human brain tumor cell line (Jazayeri et al.,
2000). These observations contradict an oncogenic role of Shp2,
indicating that the functions of Shp2 in tumorigenesis in some types
of cancer may be complicated. At present, no clear-cut mechanistic
explanation has been found to explain these paradoxical character-
istics of Shp2 mutations (Edouard et al., 2007).
To examine the role of Shp2 in a well characterized experimental
system we turned to the mouse polyoma virus middle T antigen
(PyMT). PyMT is able to transform established rodent ﬁbroblasts to a
fully transformed, tumorigenic phenotype in a dosage-dependent
fashion (Ichaso and Dilworth, 2001; Dilworth, 2002; Raptis et al.,
1985). PyMT is a cytoplasmically facing membrane bound protein
which interacts with pp60c-src and other members of the src family of
non-receptor tyrosine kinases. pp60c-src is activated in complexes
with PyMT, resulting in phosphorylation of PyMT at three distinct
sites. This leads to activation of multiple signal transduction pathways
(Fluck and Schaffhausen, 2009; Schaffhausen and Roberts, 2009
Cheng et al., 2009). The serine/threonine phosphatase PP2A binds to
both the middle and small T antigens and is needed for formation of
PyMT–Src complexes (Brewster et al., 1997; Campbell et al., 1995).
PP2A can serve this function even in a catalytically inactive form
(Ogris et al., 1999). Tyrosine substitution mutants of PyMT blocked in
speciﬁc pathways have been used to study events at the molecular
level that are essential for cell transformation in vitro and tumor
induction in the mouse. The action of Shp2, or other PTP, in this
205Y. Yang et al. / Virology 409 (2011) 204–210system may be envisaged to act at multiple levels with potentially
opposite effects on transformation. Dephosphorylation of tyrosine-
527, the autoregulatory site in pp60c-src, would be expected to activate
kinase activity toward exogenous substrates, including PyMT. De-
phosphorylation of tyrosine-419 on the other hand may block
activation (Roskoski, 2005). Dephosphorylation of PyMT at any of
the three tyrosines phosphorylated by pp60c-src is expected to be
inhibitory, in a manner dependent on cell type. The evidence is based
on tumor studies in mice with middle T mutants showing that
blocking speciﬁc signaling pathways results in changes in tissue-
speciﬁcity as well as frequency in the tumor proﬁle (Bronson et al.,
1997; Talmage et al., 1989).
To investigate the role of Shp2 in transformation, we utilized PyMT
as a model oncogene and found that Shp2 suppressed transformation
of established ﬁbroblasts by PyMT. The inhibitory effect of Shp2 was
mediated at least in part through Stat3.
Results
A catalytically inactive Shp2 mutant enhanced PyMT-induced
transformation
To assess the role of Shp2 in transformation, we ﬁrst examined the
effect of over-expression of Shp2 C/S mutant, a catalytically defective
Shp2 mutant that dominant-negatively inhibits the activity of
endogenous Shp2 (Zhang et al., 2004), on cellular transformationFig. 1. Over-expression of a dominant-negative Shp2 mutant enhanced PyMT-induced transf
(3T3/Vector) or PyMT (3T3.PyMT) as indicated. Top panel: Western blot of PyMT with tubuli
panel: Quantitative results of focus formation using NIH Image J software. Values represent r
(B) Over-expression of dominant-negative Shp2 mutant increased transformation in PyMT-t
empty vector (Vector), wild type Shp2 (Shp2WT), or Shp2 C/S mutant (Shp2 C/S). Middle pa
focus formation assays.induced by PyMT (Fig. 1A). Focus formation assays were used to
measure transformation. PyMT-transformed cells that over-express
the dominant-negative form of Shp2 formedmore and larger foci than
those which over-expressed the wild-type Shp2 or the vector alone
(Fig. 1B). Compared to the cells over-expressing wild type Shp2 or
empty vector, the PyMT-transformed cells over-expressing the Shp2
mutant became more refringent, with an elongated, spindle shape
(not shown). These observations suggested that the inhibition of Shp2
enhanced transformation induced by PyMT.
Re-introduction of Shp2 in Shp2-deﬁcient cells strongly inhibited
PyMT-induced transformation both in vitro and in vivo
To directly determine the role of Shp2 in PyMT-induced transfor-
mation, we compared the ability of PyMT to transform Shp2-deﬁcient
B1 cells, which were derived from Shp2 knockout mice, or Shp2-
rescued B1R cells (Oh et al., 1999) (Fig. 2A). Western blot analysis
suggested that the expression of exogenous Shp2 is comparable to
that of endogenous level in wild type ﬁbroblast cells (Fig. 2B). Foci
were fewer and smaller in PyMT-transformed B1R cells than in PyMT-
transformed B1 cells. These observations indicate that re-introduction
of Shp2 expression in Shp2-deﬁcient cells inhibited PyMT-induced
transformation. Importantly, PyMT-transformed B1R cells developed
tumors more slowly than PyMT-transformed B1 cells (Fig. 2C),
strongly suggesting that Shp2 plays a negative role in PyMT-induced
tumorigenesis in vivo. Interestingly, histological staining suggestedormation. (A) PyMT-induced transformation in 3T3 cells transduced with empty vector
n as a loading control. Middle panel: Focus formation assay of cells as indicated. Bottom
elative color density. Data shown are representative of three independent experiments.
ransformed 3T3 cells. Top panel: Western blot of Shp2. PyMT-3T3 cells transduced with
nel: Focus formation assays of the cells as indicated. Bottom panel: Quantitative result of
Fig. 2. Restoring Shp2 expression in Shp2-deﬁcient cells inhibited PyMT-induced transformation in vitro and in vivo. Shp2-rescued B1R cells were established by restoring Shp2
expression in Shp2-deﬁcient B1 cells. (A) PyMT-induced transformation in B1 or B1R cells transducedwith empty vector (B1/Vector or B1R/Vector) or PyMT (B1/PyMT or B1R/PyMT)
as indicated. Top panel: Western blot of PyMT or Shp2. Middle panel: Focus formation assays of cells as indicated. Bottom panel: Quantitative results of focus formation. (B) The
expression of exogenous Shp2 in B1R cell is comparable to that of endogenous level in wild type ﬁbroblast cells. Western blot analysis was performed using the antibodies as
indicated in A. (C) PyMT-induced transformation in vivo is inhibited in Shp2-rescued B1R cells. Top panel: Tumor formation in the mice subcutaneously inoculated with cells as
indicated. Pictures were taken three weeks after cell inoculation. Please note that a small pulp corresponding to B1/Vector is granulation tissue that was identiﬁed by histological
staining (data not shown). Middle panel: Quantitative result of the tumor size (n=±SD). Bottom panel: Histological H&E staining of the dissected tumors.
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different cellular morphology from that from PyMT-transformed B1
cells while both of them appeared to be ﬁbrosarcoma.Down-regulation of Shp2 expression by the shRNA also promoted
PyMT-induced transformation
To exclude the possibility that long term culture changed the
transformation activity of Shp2-deﬁcient cells, Shp2 shRNA was
utilized to determine the effect of down-regulating Shp2 on PyMT-
induced transformation in NIH3T3 cells. Western blot analysis
showed that Shp2 protein expression was signiﬁcantly down-regulated by Shp2 shRNA even at 10 days after shRNA introduction
(Fig. 3A). In accordance with the results obtained in Shp2-deﬁcient
cells, Shp2 shRNA knockdown enhanced PyMT-induced transforma-
tion compared to scrambled shRNA (Fig. 3B).Enhanced activation of Stat3 partially accounts for increased transformation
activity in PyMT-induced transformation in a Shp2-deﬁcient cell line
To understand the mechanism underlying the negative role of
Shp2 in transformation by PyMT, we ﬁrst investigated the activation
status of Erk and Akt kinases, previously shown to be regulated by
Shp2 (Zhang et al., 2002; Neel et al., 2003), in PyMT-transformed cells
Fig. 3. Shp2 knockdown enhanced PyMT-induced transformation. PyMT-transformed 3T3 cells were transduced with scrambled shRNA or Shp2 shRNA for 6 and 10 days. (A) The
knockdown efﬁciency of Shp2 shRNA. Left panel: Western blot of Shp2 and ERK2 as a loading control. Right panel: Quantitative result of the Western blots using NIH Image J
software. The value for each band represents relative band density normalized to the loading control. Data shown are representative of three independent experiments. (B) Right
panel: Focus formation assays. Left panel: Quantitative result.
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phosphorylation level of Erk kinase was lower in PyMT-transformed
B1 cells than in transformed B1R cells (Fig. 4A). PyMT expression
induced a constitutive activation of Akt (Dahl et al., 1998), with an
equal or slightly higher level in B1R cells than in B1 cells. Because Shp2
has been shown to manipulate the activation of Stat proteins (Feng,
1999), we then compared the phosphorylation level of Stat3, which is
an important regulator in ﬁbroblast transformation (Kalakonda et al.,
2007), in PyMT-transformed B1 and B1R cells. Interestingly, Stat3
phosphorylation was up-regulated in transformed B1 cells compared
to transformed B1R cells, in both the presence and absence of EGF
(Fig. 4A). Shp2 shRNA knockdown also led to similar results in PyMT-
transformed 3T3 cells (Fig. 4B). To conﬁrm the importance of Stat3 in
this transformation, we studied the effect of the Stat3 shRNA
knockdown. Down-regulation of Stat3 suppressed the PyMT-induced
transformation, bringing it to a similar level in PyMT-transformed B1
and B1R cells (Fig. 4D).
Discussion
Studies of PyMT have contributed signiﬁcantly to our understanding
of the roles of intracellular signaling pathways involving tyrosine
phosphorylation in cell transformation and tumor induction in the
mouse (Fluck and Schaffhausen, 2009; Schaffhausen and Roberts, 2009;Cheng et al., 2009). Here we have shown that the protein tyrosine
phosphatase Shp2 inhibits PyMT-induced transformation. PyMT is
among the several oncogenes associated with increased Stat3 activity
(Garcia et al., 1997). Evidence presented here indicates that the effect of
Shp2 on transformation is mediated in part through inhibition of Stat3
pathway(s). These conclusions are based on the following experimental
observations: 1) a catalytically inactive Shp2 mutant enhanced PyMT-
induced transformation; 2) the re-introduction of Shp2 into Shp2-
deﬁcient cells (Fig. 2) inhibited PyMT-induced transformation in vitro
and tumorigenesis; and 3) down regulation of Shp2 expression by the
shRNA promoted PyMT-induced transformation. The effects of Shp2 on
transformation are not likely due to the changes in PyMT expression
level (Figs. 2 and 3) or its activity (Fig. 4) caused by Shp2 gene
manipulation. Instead, deﬁciency of Shp2 led to an increase of Stat3
activation in PyMT-transformed cells and Stat3 knockdown inhibited
transformation. Although Shp2has been reported to negatively regulate
cytokine-triggered Stat pathway in lymphoid cells and astrocytes
(Gauthier et al., 2007; Sedy et al., 2005; Feng, 1999), this is the ﬁrst
report that negative regulation of a Stat pathway by Shp2 is involved
in the inhibition of transformation. It is worthy of note that the
expression level of Shp2 does not signiﬁcantly affect the anchorage-
independent growth, another transformation ability of PyMT, of
PyMT-transformed cells (data not shown) although it does affect the
tumorigenesis of PyMT-transformed cells in vivo (Fig. 2).
Fig. 4. Stat3 partially mediates the effect of Shp2 on PyMT-induced transformation. (A) The phosphorylation level of Stat3 was increased in Shp2-deﬁcient cells. The empty vector- or
PyMT-transduced B1 or B1R cells were serum-starved overnight and then stimulated with EGF (100 ng/ml), followed by Western blotting with the antibodies as indicated. Arrow
heads indicate quantitative results of phospho-Stat3. (B) Shp2 knockdown enhanced the phosphorylation of Stat3 in PyMT-expressing 3T3 cells. Western blots were performed on
3T3 cells transduced with Shp2 shRNA 6 and 10 days after infection. (C, D) Stat3 knockdown suppressed PyMT-induced transformation. PyMT-transduced B1 or B1R cells were
transduced with Scrambled or Stat3 shRNA lentiviruses, followed by Western blotting (C) or focus formation assay (D). The left panel in (D) is a quantitative result of the focus
formation.
208 Y. Yang et al. / Virology 409 (2011) 204–210Other substrates and pathways may also be involved in Shp2-
mediated inhibition of transformation. Shp2 could affect activation of
Src itself by dephosphorylating the regulatory sites at Y527 and Y419.
It has been suggested that PyMT may interact with Shp2 (Ong et al.,
2001; Fluck and Schaffhausen, 2009; Schaffhausen and Roberts, 2009;
Cheng et al., 2009 ). Dephosphorylation of PyMT by Shp2 at any of the
three tyrosines phosphorylated by Src would be expected to havedifferential effects on cell transformation and tumor induction,
depending on the target cell.
The inhibitory effects of Shp2 on transformation of established
ﬁbroblasts may not be predictive of its effects on oncogenic
transformation in vivo, as indicated by results with the polyoma
virus middle T mutant 250YS. Substitution of Y250, or mutations of
residues immediately upstream, strongly inhibits transformation of
209Y. Yang et al. / Virology 409 (2011) 204–210established rodent ﬁbroblasts (Druker et al., 1992; Dahl et al., 1996;
Dilworth et al., 1994) and endothelial cells (Ong et al., 2001).
Phosphorylation at this site promotes binding of ShcA and may also
recruit Shp2 through interaction with adaptors Grb2–Gab1. Surpris-
ingly, the non-transforming 250YS mutant virus is highly tumorigenic
in the mouse (Bronson et al., 1997). This mutant induces tumors
broadly but with differences from the wild type virus in terms of the
spectrum, frequencies and biological behavior of speciﬁc tumor types.
Tumor formation is more pronounced at some sites and less
pronounced at others compared to the spectrum induced by the
wild type virus. Paradoxically, though unable to transform ﬁbroblasts
in culture, the mutant induces subcutaneous ﬁbrosarcomas more
efﬁciently than the wild type virus. Clearly, the operation of particular
pathways leads to different outcomes in tumor development
depending on the cell type and tissue context. Further studies on
signaling pathways downstream of Y250 in PyMT and identiﬁcation of
Shp2 substrate(s) will be required to fully deﬁne the mechanism(s) of
Shp2 signaling in transformation. Further investigations will also be
needed to determine whether Shp2 plays a negative or positive role in
the development of particular human tumors.
Materials and methods
Reagents and antibodies
Dulbecco's modiﬁed Eagle's medium (DMEM)was purchased from
Invitrogen (Carlsbad, CA); fetal calf serum (FCS) was purchased from
Hyclone (Logan, UT). Transfection reagent Fugene 6 was from Roche
Applied Science (Herndon, VA). The antibodies against phospho-
Stat3, phospho-Akt and phospho-MAPK for Western blotting were
purchased from Cell Signaling Technology (Beverly, MA). The
antibodies against Shp2, Stat3, Akt and Erk2 were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA), except for the F4 mouse
monoclonal antibody against PyMT (Pallas et al., 1986).
Cell lines and plasmids
Mouse embryo ﬁbroblast cell line, NIH3T3, was cultured in DMEM
containing 10% FCS in a 5% CO2-humidiﬁed atmosphere at 37 °C. B1
cell line, Shp2-deﬁcient embryo ﬁbroblast, was derived from
Shp2△46–110 (Shp2−/−) mice; B1R cell line was from the B1 cell
line rescued by re-introduction of wild-type Shp2 gene (Zhang et al.,
2002). To establish PyMT-expressing stable cell lines, NIH3T3, B1 and
B1R cells were infected by retrovirus-containing supernatant from
293 T cell lines, which were co-transfected with the plasmids of
retroviral pPinco/PyMT or empty pPinco vector and the packaging
plasmids as described before (Yu et al., 2006). Infected cells were
selected in the presence of 1.1 μg/ml of puromycin (Sigma; St. Louis,
MO) for 1 week. The same approach was used to express exogenously
wild type Shp2 (Shp2 WT) or the dominant-negative Shp2 C/S
mutants (Shp2 C/S) in NIH3T3 cells.
Construction and transient expression of small hairpin RNAs (shRNAs) of
Shp2 and Stat3 in ﬁbroblasts
Sequences for targeting genes and the scrambled control were
selected according to an open program (http://jura.wi.mit.edu/bioc/
siRNAext/). The shRNA sequence of Shp2 is 5′-GGACATGAAT-
ATACCAATATT-3′; the shRNA sequence of Stat3 is GTCAGG-
TTGCTGGTCAAATTT-3′; and the control scrambled sequence is 5′-
CCTAAGGTTAAGTCGCCCTCG-3′. Sense and antisense oligonucleotides
were synthesized, annealed, and inserted into a lentiviral vector
pLKO1 (Sigma). The nucleotide sequences of the inserts were
conﬁrmed by sequencing analysis. Preparation of lenti viruses and
infection of PyMT-transformed 3T3 cells were carried out as described
(Durocher et al., 2002). The plasmids of shRNA or control vectorsweretransfected into 293 T cells to produce lenti virus by using a PEI
transfection method (Xiong et al., 2009).
Western blot assay
Cells were lysed in 1% Nonidet P-40 (Calbiochem, San Diego, CA)
buffer containing 150 mMNaCl, 50 mM Tris–HCl, pH 7.4, 5 mM EDTA,
1% Nonidet P-40, 1 mM NaVO3, 20 mM NaF, 1 mM benzamidine,
1 mM phenylmethylsulfonyl ﬂuoride, 1 μg/ml of pepstatin A, 5 μg/ml
of aprotinin, and 5 μg/ml of leupeptin on ice. Cell lysates were clariﬁed
by centrifugation at 15,000 rpm at 4 °C for 20 min. The protein con-
centration was determined using the BCA™ protein assay kit
according to the manufacturer's instructions (Pierce, Rockford, IL).
Lysates were subjected to SDS-PAGE electrophoresis, followed by
Western blot analysis using a standard protocol (Luo et al., 1998).
Focus formation assay
Focus formation assays were performed as describe previously
with minor modiﬁcations (Ischenko et al., 2003). Brieﬂy, 5×103 cells
stably expressing PyMT were plated on 6 cm dishes together with
5×104 parental NIH3T3 cells. The cells were grown in DMEM
supplemented with 5% FCS, 100 μg/ml of streptomycin, and 100 U/
ml of penicillin for 10 days and the medium was changed every three
days. Plates were washed with PBS and ﬁxed in ice-cold methanol for
10 min. Foci were stained with crystal violet (Sigma), photographed
and counted under a low-power microscope. Quantitative analysis of
focus formation was carried out using NIH Image J software.
Nude mouse tumor xenograft model
A total of 1×107 cells (in 100 μl of PBS) expressing PyMT or empty
vector were inoculated subcutaneously in BALB/c nude mice (n=4).
The tumor size was measured from day three after cell inoculation.
Mice were sacriﬁced three weeks after inoculation. The volume and
weight of the tumors was measured and compared. Dissected tumor
tissue was ﬁxed in formalin, embedded in parafﬁn, stained with
hematoxylin and eosin (H&E) using standard techniques.
Statistical analyses
Group differences were analyzed by a standard Student T test. All
values are expressed as mean±SD. Statistical signiﬁcance was set at a
P-value less than 0.05 (*) or 0.01 (**).
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